leadf
logo-loader
viewPrescient Therapeutics Ltd

Prescient Therapeutics has path forward as they look to future of cancer treatments

Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive to share details about the company that is personalizing cancer treatment using CAR-T cell therapy.

Yatomi -Clarke telling Proactive about their work and also some recent big news for the company including being issued two U.S. patents.

Quick facts: Prescient Therapeutics Ltd

Price: 0.069 AUD

ASX:PTX
Market: ASX
Market Cap: $44.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Venture Minerals says Golden Grove North could host significant body of VMS...

Venture Minerals Limited's (ASX:VMS) Andrew Radonjic sat down with Proactive's Andrew Scott after confirming a volcanic massive sulphide (VMS) system with assays of up to 7% zinc in its maiden drilling at the Orcus prospect within the Golden Grove North Project in WA. All three holes returned...

1 day, 7 hours ago

2 min read